You are here:

methylphenidate HCI Prolonged release (Medikinet XL)

Advice

Following an abbreviated submission

Methylphenidate prolonged-release capsule (Medikinet XL®) is accepted for restricted use within NHS Scotland as part of a comprehensive treatment programme for attention deficit hyperactivity disorder (ADHD) in children over 6 years of age when remedial measures alone prove insufficient.

Like other modified release methylphenidate formulations, it should be considered second line and used for patients requiring methylphenidate in the morning and afternoon when administration of a midday dose is problematic or inappropriate. Treatment should be under the supervision of a specialist in childhood behaviour disorders. The pharmacokinetic profile of Medikinet XL® differs from those of other modified release formulations of methylphenidate.

Drug Details

Drug Name: methylphenidate HCI Prolonged release (Medikinet XL)
SMC Drug ID: 388/07
Manufacturer: UK Distributer Flynn Pharma Ltd
Indication: attention deficit hyperactivity disorder (ADHD) in children over 6 years of age
BNF Category:
Sub Category: 4.4 CNS stimulants and drugs used for attention deficit hyperactivity disorder
Submission Type: Abbreviated Submission
Status: Restricted
Date Advice Published: 9 July 2007

Back